Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Stephen A. Cannistra, M.D.


This page shows the publications co-authored by Stephen Cannistra and Panagiotis Konstantinopoulos.
  1. Immune Checkpoint Inhibitors in Ovarian Cancer: Can We Bridge the Gap Between IMagynation and Reality? J Clin Oncol. 2021 06 10; 39(17):1833-1838.
    View in: PubMed
    Score: 0.960
  2. Bevacizumab rechallenge after first line maintenance bevacizumab. Gynecol Oncol. 2012 May; 125(2):510-1.
    View in: PubMed
    Score: 0.508
  3. Comparing poly (ADP-ribose) polymerase inhibitors with standard chemotherapy in BRCA-mutated, recurrent ovarian cancer: lessons learned from a negative trial. J Clin Oncol. 2012 Feb 01; 30(4):347-50.
    View in: PubMed
    Score: 0.503
  4. Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer. Cancer Res. 2011 Aug 01; 71(15):5081-9.
    View in: PubMed
    Score: 0.485
  5. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol. 2010 Aug 01; 28(22):3555-61.
    View in: PubMed
    Score: 0.452
  6. Gene-expression profiling in epithelial ovarian cancer. Nat Clin Pract Oncol. 2008 Oct; 5(10):577-87.
    View in: PubMed
    Score: 0.397
  7. Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer. J Clin Oncol. 2019 10 20; 37(30):2786-2794.
    View in: PubMed
    Score: 0.214
  8. Integrated analysis of multiple microarray datasets identifies a reproducible survival predictor in ovarian cancer. PLoS One. 2011 Mar 29; 6(3):e18202.
    View in: PubMed
    Score: 0.119
  9. Carboplatin-induced gene expression changes in vitro are prognostic of survival in epithelial ovarian cancer. BMC Med Genomics. 2008 Nov 28; 1:59.
    View in: PubMed
    Score: 0.102
  10. Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2019 12 01; 5(12):1731-1738.
    View in: PubMed
    Score: 0.054
  11. Laparoscopic intraperitoneal port placement for optimally cytoreduced advanced ovarian cancer. J Minim Invasive Gynecol. 2011 Sep-Oct; 18(5):629-33.
    View in: PubMed
    Score: 0.031
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.